Prof. Nutt appointed Head of Research to Lead Awakn’s Next-Gen Psychedelic Molecule Development
Awakn Life Sciences announces the acquisition of significant proprietary research data on next generation candidate MDMA and Ketamine molecules from Prof. David Nutt’s Equasy Enterprises. In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn’s next generation psychedelic molecule development programme.
This latest development adds significantly to Awakn’s already strong research programmes, with the world’s first Phase II b MDMA-Assisted Psychotherapy trial initiated and further research planned on Ketamine-Assisted Psychotherapy. This milestone is in addition to Awakn’s recently announced exclusive licence of the intellectual property from the world’s only phase IIab trial of ketamine for Alcohol Use Disorder from the University of Exeter.
Prof. Nutt, Head of Research and Chair of the Scientific Advisory Board, Awakn Life Sciences, states, “I have worked in novel psychopharmacological molecule development for many years and have completed over 5 years of research specifically on next generation MDMA and Ketamine candidate molecules. I am delighted to be able to bring the research forward, to lead this activity in Awakn, and to significantly accelerate the development of new compounds to better treat Addiction.”
Anthony Tennyson, CEO Awakn Life Sciences, comments, “This is another great step forward for Awakn. Adding Next-Gen Psychedelic Molecule Development to our already strong research division and soon to be launched UK and EU clinics platform positions us firmly in the top tier of this industry.”